Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17868276 | 0.73 | HRH3 (0.47) | — | |
| SCHEMBL10820260 | 0.66 | DRD2 (0.65) | DRD2DRD4 | |
| SCHEMBL19262539 | 0.66 | DRD2 (0.69) | DRD2DRD4 | |
| SCHEMBL22335162 | 0.66 | DRD2 (0.69) | DRD2DRD4 | |
| SCHEMBL6925295 | 0.66 | DRD2 (0.69) | DRD2DRD4 | |
| SCHEMBL445421 | 0.66 | DRD2 (0.69) | DRD2DRD4 | |
| SCHEMBL7292211 | 0.65 | DRD2 (0.49) | DRD2DRD4 | |
| SCHEMBL13898517 | 0.64 | CCR5 (0.60) | DRD2DRD4 | |
| SCHEMBL3892595 | 0.64 | CCR5 (0.60) | DRD2DRD4 | |
| SCHEMBL18926528 | 0.63 | DHFR (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190031653-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | NOVIRA THERAPEUTICS, INC. | 2019-01-31 | — | — | US | disclosed |
| EP-3240787-A2 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | Novira Therapeutics Inc. (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20160185779-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031653-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | HAVCR2, PYGL, HCCS | DRD2 4709/4885DRD4 4502/4885 |
| US-20160185779-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | DRD2 4709/4885DRD4 4502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.